EO 14398 - this project shall sequence and characterize the genome of bdbv in the current outbreak, with a specific target to sequence and analyze the bdbv genome from as many as 1,000 patients
Active Definitive Contract Awarded Last action
- Contract number
- 75F40126C00106
- Awardee
-
University Of Liverpool UEI VFHSMEHGFGG5
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $349,995
Award facts
- Opportunity
-
- Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak Solicitation · 75F40126Q00327 · Posted Aug 4, 2026
- Contract value 100% obligated
- $349,994.70 Current and potential, with all options
- Completion date 41% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Great Britain, United Kingdom
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The Food and Drug Administration awarded a $349,994.70 definitive contract to University Of Liverpool for sequencing and genomic characterization of Bundibugyo virus disease (BDBV) from clinical samples on August 21, 2026, with an ultimate completion date of February 20, 2027.
The originating solicitation, posted August 4, 2026 with proposals due August 10, calls for high-quality, full-genome BDBV sequence data from up to 1,000 human clinical samples collected during an ongoing outbreak in the Democratic Republic of Congo and Uganda. Work employs Illumina NovaSeq X plus and Oxford Nanopore P2 PromethION sequencing technologies to generate short and long read data identifying minor variants and mutational linkages. The contractor will upload all data to NCBI GeneBank and FDA-ARGOS databases, compare BDBV sequences to assess genomic differences from previous outbreaks and Ebola virus, and conduct phylogenetic and in silico genotype-to-phenotype analysis. Performance runs from August 17 through December 31, 2026, with no options. Place of performance is Great Britain, United Kingdom. NAICS code 541714 (Research and Development in Biotechnology); PSC code AN13 (Health R&D Services). The contract mandates extensive security compliance including FISMA, NIST standards, FAR regulations, and HHS/FDA Information Security and Privacy Protection policies, with contractor personnel required to maintain Authority to Operate, protect Controlled Unclassified Information, implement FIPS 140-validated encryption, and conduct annual security assessments and penetration testing.
Quick answers
Who was awarded contract 75F40126C00106?
75F40126C00106 was awarded to University Of Liverpool by Food and Drug Administration (Department of Health and Human Services) on August 21, 2026.
How much is contract 75F40126C00106 worth?
The government has obligated $349,995 on 75F40126C00106.
Was contract 75F40126C00106 competed?
The extent of competition for 75F40126C00106 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award